Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.49 +1.0%	$1.31	$1.05 ▼ $5.17	$160.80M	0.41	1.19 million shs	266,330 shs
BCAX Bicara Therapeutics	$10.54 -2.8%	$12.40	$7.80 ▼ $28.09	$574.76M	N/A	581,122 shs	151,251 shs
SANA Sana Biotechnology	$2.53 -2.5%	$1.96	$1.26 ▼ $7.40	$569.33M	1.78	3.55 million shs	1.28 million shs
TRVI Trevi Therapeutics	$6.16 +1.1%	$6.29	$2.36 ▼ $7.48	$726.04M	0.59	1.35 million shs	434,219 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-3.92%	+12.21%	-6.96%	+24.58%
BCAX Bicara Therapeutics	0.00%	-5.74%	-25.09%	-19.70%	+1,083,999,900.00%
SANA Sana Biotechnology	0.00%	-8.80%	+48.42%	-6.50%	-57.40%
TRVI Trevi Therapeutics	0.00%	-13.74%	-6.31%	-6.88%	+129.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.6026 of 5 stars	3.6	1.0	3.0	1.7	1.3
BCAX Bicara Therapeutics	2.2519 of 5 stars	3.5	0.0	3.2	0.8	0.6
SANA Sana Biotechnology	1.9144 of 5 stars	3.4	0.0	1.5	3.3	0.6
TRVI Trevi Therapeutics	3.6432 of 5 stars	4.7	2.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	554.16% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	202.26% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	327.72% Upside
TRVI Trevi Therapeutics	3.33	Buy	$20.29	229.58% Upside

Current Analyst Ratings Breakdown

Latest ACRS, SANA, TRVI, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	9.05	N/A	N/A	$2.22 per share	0.67
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$88.48M	-$1.39	N/A	N/A	N/A	-136.65%	-40.26%	-31.71%	8/6/2025 (Estimated)
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	8/6/2025 (Estimated)
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	8/6/2025 (Estimated)

Latest ACRS, SANA, TRVI, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	7.03	7.03
BCAX Bicara Therapeutics	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	4.47	4.47
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
BCAX Bicara Therapeutics	N/A
SANA Sana Biotechnology	88.23%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
BCAX Bicara Therapeutics	15.50%
SANA Sana Biotechnology	30.10%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	66.86 million	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	58.13 million	Optionable

ACRS, SANA, TRVI, and BCAX Headlines

Recent News About These Companies

Q2 EPS Estimate for Trevi Therapeutics Lifted by Analyst

June 15 at 1:45 AM | americanbankingnews.com

Leerink Partnrs Has Bullish Forecast for TRVI Q2 Earnings

June 13 at 5:50 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

June 9, 2025 | marketbeat.com

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 9, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

June 8, 2025 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's Why

June 3, 2025 | marketbeat.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?

June 2, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital

June 2, 2025 | marketbeat.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

June 1, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TRVI Q2 Earnings

May 31, 2025 | marketbeat.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, SANA, TRVI, and BCAX Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.48 +0.02 (+1.02%)

As of 12:17 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Bicara Therapeutics NASDAQ:BCAX

$10.54 -0.30 (-2.77%)

As of 12:17 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$2.52 -0.07 (-2.51%)

As of 12:17 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Trevi Therapeutics NASDAQ:TRVI

$6.16 +0.07 (+1.07%)

As of 12:17 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time